MCID: BLD047
MIFTS: 43

Bladder Squamous Cell Carcinoma

Categories: Cancer diseases, Nephrological diseases, Skin diseases

Aliases & Classifications for Bladder Squamous Cell Carcinoma

MalaCards integrated aliases for Bladder Squamous Cell Carcinoma:

Name: Bladder Squamous Cell Carcinoma 12 14 69
Epidermoid Carcinoma of the Urinary Bladder 12
Squamous Cell Carcinoma of Bladder 12
Carcinoma Squamous Cell Bladder 51

Classifications:



External Ids:

Disease Ontology 12 DOID:3742
NCIt 46 C4031
SNOMED-CT 64 255111004
UMLS 69 C0279681

Summaries for Bladder Squamous Cell Carcinoma

Disease Ontology : 12 A carcinoma of bladder that is manifested in squamous cells of the bladder.

MalaCards based summary : Bladder Squamous Cell Carcinoma, also known as epidermoid carcinoma of the urinary bladder, is related to transitional cell carcinoma and squamous cell carcinoma, and has symptoms including dysuria An important gene associated with Bladder Squamous Cell Carcinoma is S100A7 (S100 Calcium Binding Protein A7), and among its related pathways/superpathways are Endometrial cancer and PI3K-Akt signaling pathway. The drugs Epirubicin and Fluorouracil have been mentioned in the context of this disorder. Affiliated tissues include lung, kidney and lymph node, and related phenotypes are muscle and neoplasm

Related Diseases for Bladder Squamous Cell Carcinoma

Diseases related to Bladder Squamous Cell Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 89)
# Related Disease Score Top Affiliating Genes
1 transitional cell carcinoma 29.4 PTGS2 TP53 UPK2
2 squamous cell carcinoma 29.2 CDKN2A PTEN PTGS2 S100A7 TP53
3 papilloma 29.2 CDKN2A PTEN TP53
4 retroperitoneum carcinoma 10.5 CDKN2A UPK2
5 endometrial squamous cell carcinoma 10.4 CDKN2A HGF
6 chronic myocardial ischemia 10.3 FGF2 HGF
7 acral lentiginous melanoma 10.2 CDKN2A PTEN
8 bowenoid papulosis 10.2 CDKN2A PTGS2
9 clivus chordoma 10.2 FGF2 PTEN
10 cervical adenosquamous carcinoma 10.1 CDKN2A PTGS2
11 brain stem astrocytic neoplasm 10.1 CDKN2A TP53
12 squamous cell carcinoma of the oropharynx 10.1 CDKN2A TP53
13 spitz nevus 10.1 CDKN2A TP53
14 keratinizing squamous cell carcinoma 10.1 CDKN2A TP53
15 squamous cell carcinoma of the larynx 10.1 CDKN2A TP53
16 bartholin's gland benign neoplasm 10.1 CDKN2A TP53
17 anal squamous cell carcinoma 10.0 CDKN2A TP53
18 thyroid lymphoma 10.0 CDKN2A TP53
19 vulva squamous cell carcinoma 10.0 CDKN2A TP53
20 nasal cavity adenocarcinoma 10.0 CDKN2A TP53
21 bone squamous cell carcinoma 10.0 CDKN2A TP53
22 megaesophagus 10.0 CDKN2A TP53
23 scrotal carcinoma 10.0 CDKN2A TP53
24 pilocytic astrocytoma 10.0 CDKN2A FGF2 PTEN
25 glycogen-rich clear cell breast carcinoma 10.0 CDKN2A TP53
26 oral leukoplakia 10.0 CDKN2A TP53
27 anogenital venereal wart 10.0 CDKN2A TP53
28 cervix uteri carcinoma in situ 10.0 CDKN2A TP53
29 small cell neuroendocrine carcinoma 10.0 CDKN2A TP53
30 meningeal melanomatosis 10.0 CDKN2A TP53
31 dedifferentiated liposarcoma 10.0 CDKN2A TP53
32 suppressor of tumorigenicity 3 9.9 CDKN2A TP53
33 pre-malignant neoplasm 9.9 CDKN2A S100A7 TP53
34 oropharynx cancer 9.9 CDKN2A TP53
35 bladder carcinoma in situ 9.9 CDKN2A TP53 UPK2
36 female reproductive endometrioid cancer 9.9 PTEN TP53
37 gastric ulcer 9.9 FGF2 HGF PTGS2
38 endocervical adenocarcinoma 9.9 CDKN2A TP53
39 synchronous bilateral breast carcinoma 9.9 PTEN TP53
40 small cell sarcoma 9.9 CDKN2A TP53
41 protoplasmic astrocytoma 9.8 PTGS2 TP53
42 cervix small cell carcinoma 9.8 CDKN2A TP53
43 chronic leukemia 9.8 HGF PTEN PTGS2
44 juvenile pilocytic astrocytoma 9.8 CDKN2A FGF2 TP53
45 schistosoma mansoni infection, susceptibility/ 9.8
46 neural tube defects 9.8
47 episodic pain syndrome, familial, 1 9.8
48 urinary schistosomiasis 9.8
49 schistosomiasis 9.8
50 enterovesical fistula 9.8

Graphical network of the top 20 diseases related to Bladder Squamous Cell Carcinoma:



Diseases related to Bladder Squamous Cell Carcinoma

Symptoms & Phenotypes for Bladder Squamous Cell Carcinoma

UMLS symptoms related to Bladder Squamous Cell Carcinoma:


dysuria

MGI Mouse Phenotypes related to Bladder Squamous Cell Carcinoma:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 muscle MP:0005369 9.43 CDKN2A FGF2 HMBS PTEN PTGS2 TP53
2 neoplasm MP:0002006 9.02 CDKN2A FGF2 PTEN PTGS2 TP53

Drugs & Therapeutics for Bladder Squamous Cell Carcinoma

Drugs for Bladder Squamous Cell Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 60)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Epirubicin Approved Phase 3 56420-45-2 41867
2
Fluorouracil Approved Phase 3 51-21-8 3385
3
BCG vaccine Investigational Phase 3
4 Adjuvants, Immunologic Phase 3
5 Alkylating Agents Phase 3,Phase 2
6 Anti-Bacterial Agents Phase 3
7 Antibiotics, Antitubercular Phase 3
8 Anti-Infective Agents Phase 3,Phase 2,Phase 1
9 Antiviral Agents Phase 3,Phase 2
10 Interferon-alpha Phase 3
11 interferons Phase 3
12 Mitomycins Phase 3
13 Nucleic Acid Synthesis Inhibitors Phase 3
14 Pharmaceutical Solutions Phase 3
15 Topoisomerase Inhibitors Phase 3,Phase 2
16 Vaccines Phase 3,Phase 1
17 Antimetabolites Phase 3,Phase 2
18 Antimetabolites, Antineoplastic Phase 3,Phase 2
19 Immunosuppressive Agents Phase 3,Phase 2
20
Carboplatin Approved Phase 2 41575-94-4 10339178 38904 498142
21
Gemcitabine Approved Phase 2 95058-81-4 60750
22
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
23
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
24
Cisplatin Approved Phase 2 15663-27-1 2767 441203 84093
25
Ifosfamide Approved Phase 2 3778-73-2 3690
26
Mechlorethamine Approved, Investigational Phase 2 51-75-2 4033
27
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
28
Folic Acid Approved, Nutraceutical, Vet_approved Phase 2 59-30-3 6037
29
leucovorin Approved, Nutraceutical Phase 2 58-05-9 143 6006
30
Niacin Approved, Investigational, Nutraceutical Phase 2 59-67-6 938
31
Nicotinamide Approved, Investigational, Nutraceutical Phase 2 98-92-0 936
32 Piritrexim Investigational Phase 2 72732-56-0
33
Camptothecin Experimental Phase 2 7689-03-4
34 Albumin-Bound Paclitaxel Phase 2
35 Antimitotic Agents Phase 2
36 Antineoplastic Agents, Phytogenic Phase 2
37 Folic Acid Antagonists Phase 2
38 Vitamin B Complex Phase 2
39 Rubitecan Phase 2
40 topoisomerase I inhibitors Phase 2
41 Isophosphamide mustard Phase 2 0
42 Micronutrients Phase 2
43 Nicotinic Acids Phase 2
44 Protein Kinase Inhibitors Phase 2
45 Trace Elements Phase 2
46 Vitamins Phase 2
47 Folate Nutraceutical Phase 2
48 Vitamin B9 Nutraceutical Phase 2
49 Vitamin B3 Nutraceutical Phase 2
50
nivolumab Approved Phase 1 946414-94-4

Interventional clinical trials:

(show all 19)

# Name Status NCT ID Phase Drugs
1 Hyperthermia and Mitomycin C, Bacillus Calmette-Guerin, or Standard Therapy as Second-Line Therapy in Treating Patients With Recurrent Bladder Cancer Unknown status NCT01094964 Phase 3 epirubicin hydrochloride;mitomycin C
2 Radiation Therapy With or Without Chemotherapy in Treating Patients With Stage II or Stage III Bladder Cancer Completed NCT00024349 Phase 3 fluorouracil;mitomycin C
3 Standard Surgery or Minimal-Access Surgery in Treating Patients With Bladder Cancer Unknown status NCT01196403 Phase 2
4 Trastuzumab and Combination Chemotherapy in Treating Patients With Locally Recurrent or Metastatic Urinary Tract Cancer Completed NCT00005831 Phase 2 paclitaxel;carboplatin;gemcitabine hydrochloride
5 VEGF Trap in Treating Patients With Recurrent, Locally Advanced, or Metastatic Cancer of the Urothelium Completed NCT00407485 Phase 2
6 Piritrexim in Treating Patients With Advanced Cancer of the Urinary Tract Completed NCT00002914 Phase 2 piritrexim
7 S0121, Neoadjuvant Carboplatin, Paclitaxel, and Gemcitabine Followed by Cisplatin and Radiation Therapy in Treating Patients With Locally Advanced or Recurrent Carcinoma of the Urothelium Completed NCT00055835 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride;paclitaxel
8 Nitrocamptothecin in Treating Patients With Metastatic Cancer of the Urinary Tract Completed NCT00006026 Phase 2 rubitecan
9 Combination Chemotherapy in Patients With Advanced Urinary Tract Cancer Completed NCT00002684 Phase 2 cisplatin;ifosfamide;paclitaxel
10 Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Recruiting NCT03430895 Phase 2 durvalumab and tremelimumab
11 Gemcitabine Hydrochloride and Cisplatin Before Surgery in Treating Patients With Muscle Invasive Bladder Cancer Terminated NCT01611662 Phase 2 gemcitabine hydrochloride;cisplatin
12 Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium Terminated NCT00112905 Phase 2 sorafenib tosylate
13 S0028, Gemcitabine and Paclitaxel in Treating Patients With Advanced or Recurrent Cancer of the Urinary Tract Terminated NCT00022633 Phase 2 gemcitabine hydrochloride;paclitaxel
14 3-Dimensional Conformal Radiation Therapy in Treating Patients With Bladder Cancer Who Have Undergone Transurethral Resection of the Bladder Unknown status NCT01124682 Phase 1
15 Interleukin-2 Combined With Monoclonal Antibody Therapy in Treating Patients With Kidney, Bladder, or Lung Cancer That Has Not Responded to Previous Treatment Completed NCT00016237 Phase 1
16 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1 Cabozantinib S-malate
17 Neoadjuvant Intravesical Vaccine Therapy in Treating Patients With Bladder Carcinoma Who Are Undergoing Cystectomy Terminated NCT00072137 Phase 1
18 OX-40 Protein Expression in the Sentinel Lymph Nodes of Patients With Cancer Completed NCT00900302
19 Adjuvant Radiation for High Risk Bladder Cancer Recruiting NCT01954173

Search NIH Clinical Center for Bladder Squamous Cell Carcinoma

Genetic Tests for Bladder Squamous Cell Carcinoma

Anatomical Context for Bladder Squamous Cell Carcinoma

MalaCards organs/tissues related to Bladder Squamous Cell Carcinoma:

38
Lung, Kidney, Lymph Node

Publications for Bladder Squamous Cell Carcinoma

Articles related to Bladder Squamous Cell Carcinoma:

(show all 17)
# Title Authors Year
1
Risk factors for development of primary bladder squamous cell carcinoma. ( 27869492 )
2016
2
Bladder squamous cell carcinoma in pregnancy. ( 26467844 )
2015
3
Vesicoenteric fistula due to bladder squamous cell carcinoma. ( 25045451 )
2014
4
Radiation treatment of bladder squamous cell carcinoma in a patient with spina bifida: A case report. ( 22709884 )
2012
5
Urinary schistosomiasis with simultaneous bladder squamous cell carcinoma and transitional cell carcinoma. ( 23109968 )
2012
6
p16 expression is not associated with human papillomavirus in urinary bladder squamous cell carcinoma. ( 22684221 )
2012
7
Enterovesical fistula caused by a bladder squamous cell carcinoma. ( 19725163 )
2009
8
Bladder squamous cell carcinoma. ( 15143234 )
2004
9
Bladder squamous cell carcinoma biomarkers derived from proteomics. ( 10892722 )
2000
10
Psoriasin (S100A7): a putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. ( 10197442 )
1999
11
Enhanced tumorigenicity of rat bladder squamous cell carcinoma cells after abrogation of gap junctional intercellular communication. ( 9685850 )
1998
12
Uroplakin II gene is expressed in transitional cell carcinoma but not in bilharzial bladder squamous cell carcinoma: alternative pathways of bladder epithelial differentiation and tumor formation. ( 9515818 )
1998
13
Proteome profiling of bladder squamous cell carcinomas: identification of markers that define their degree of differentiation. ( 9307301 )
1997
14
Bladder squamous cell carcinomas express psoriasin and externalize it to the urine. ( 8618345 )
1996
15
Bladder squamous cell carcinoma with human papilloma virus type 6 [HPV 6]. ( 8749958 )
1995
16
UNME/K1: an IgG2a monoclonal antibody specific to cytokeratin of human urinary bladder squamous cell carcinoma. ( 1712997 )
1991
17
Dramatic palliation for painful, fixed bladder squamous cell carcinoma with 5-fluorouracil infusion. ( 71361 )
1977

Variations for Bladder Squamous Cell Carcinoma

Cosmic variations for Bladder Squamous Cell Carcinoma:

9 (show all 42)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA Conf
1 COSM10719 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.811G>A p.E271K 15
2 COSM45284 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.813G>A p.E271E 15
3 COSM45299 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.831T>G p.C277W 15
4 COSM10801 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.404G>A p.C135Y 15
5 COSM10738 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.542G>A p.R181H 15
6 COSM45138 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.853G>C p.E285Q 15
7 COSM10660 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.818G>A p.R273H 15
8 COSM44023 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.560G>A p.G187D 15
9 COSM46303 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.1031T>G p.L344R 15
10 COSM45285 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.795G>C p.L265L 15
11 COSM44117 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.775G>A p.D259N 15
12 COSM10704 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.844C>T p.R282W 15
13 COSM45293 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.407A>G p.Q136R 15
14 COSM10722 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.853G>A p.E285K 15
15 COSM10648 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.524G>A p.R175H 15
16 COSM10709 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.722C>G p.S241C 15
17 COSM43616 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.704A>G p.N235S 15
18 COSM10812 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.722C>T p.S241F 15
19 COSM44469 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.812A>T p.E271V 15
20 COSM45248 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.805A>T p.S269C 15
21 COSM10790 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.455C>T p.P152L 15
22 COSM10705 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.586C>T p.R196* 15
23 COSM11491 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.743G>C p.R248P 15
24 COSM44950 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.862A>G p.N288D 15
25 COSM43565 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.857A>G p.E286G 15
26 COSM44091 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.746G>A p.R249K 15
27 COSM44525 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.709A>G p.M237V 15
28 COSM44451 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.874A>G p.K292E 15
29 COSM10728 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.839G>A p.R280K 15
30 COSM10654 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.637C>T p.R213* 15
31 COSM44202 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.550G>T p.D184Y 15
32 COSM44603 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.835G>A p.G279R 15
33 COSM43963 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.396G>C p.K132N 15
34 COSM45286 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.475G>T p.A159S 15
35 COSM43660 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.719G>T p.S240I 15
36 COSM10810 TP53 urinary tract,bladder,carcinoma,squamous cell carcinoma c.725G>T p.C242F 15
37 COSM763 PIK3CA urinary tract,bladder,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 15
38 COSM488 HRAS urinary tract,bladder,carcinoma,squamous cell carcinoma c.37G>T p.G13C 15
39 COSM715 FGFR3 urinary tract,bladder,carcinoma,squamous cell carcinoma c.746C>G p.S249C 15
40 COSM19500 CDH1 urinary tract,bladder,carcinoma,squamous cell carcinoma c.2537G>C p.S846T 15
41 COSM125370 urinary tract,bladder,carcinoma,squamous cell carcinoma c.1633G>A p.E545K 15
42 COSM550 KRAS urinary tract,bladder,carcinoma,undifferentiated carcinoma c.181C>G p.Q61E 12

Expression for Bladder Squamous Cell Carcinoma

Search GEO for disease gene expression data for Bladder Squamous Cell Carcinoma.

Pathways for Bladder Squamous Cell Carcinoma

Pathways related to Bladder Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.77 CDKN2A FGF2 HGF PTEN TP53
2
Show member pathways
12.59 FGF2 HGF PTEN PTGS2 TP53
3
Show member pathways
12.5 FGF2 HGF PTEN TP53
4
Show member pathways
12.48 HGF PTEN PTGS2 TP53
5
Show member pathways
12.25 FGF2 PTEN PTGS2 TP53
6
Show member pathways
12.22 CDKN2A FGF2 HGF PTEN TP53
7 12.1 CDKN2A PTEN PTGS2 TP53
8 11.96 CDKN2A PTEN TP53
9 11.83 HGF PTEN TP53
10 11.82 CDKN2A PTEN TP53
11 11.82 CDKN2A FGF2 HGF PTEN PTGS2 TP53
12 11.75 CDKN2A PTEN TP53
13 11.7 CDKN2A PTEN TP53
14 11.66 CDKN2A PTEN TP53
15 11.55 PTEN PTGS2 TP53
16 11.38 FGF2 HGF PTGS2
17 11.31 FGF2 HGF PTGS2 TP53
18 10.92 CDKN2A TP53
19
Show member pathways
10.91 CDKN2A TP53

GO Terms for Bladder Squamous Cell Carcinoma

Biological processes related to Bladder Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

(show all 12)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.81 HGF PTEN PTGS2 TP53
2 positive regulation of cell proliferation GO:0008284 9.8 FGF2 HGF PTEN PTGS2
3 negative regulation of cell proliferation GO:0008285 9.76 CDKN2A PTEN PTGS2 TP53
4 aging GO:0007568 9.65 PTEN PTGS2 TP53
5 positive regulation of apoptotic process GO:0043065 9.62 CDKN2A PTEN PTGS2 TP53
6 response to organic cyclic compound GO:0014070 9.61 PTEN PTGS2 TP53
7 response to ethanol GO:0045471 9.54 PTEN SDF4 TP53
8 cellular response to hypoxia GO:0071456 9.43 PTEN PTGS2 TP53
9 response to inorganic substance GO:0010035 9.4 PTEN TP53
10 replicative senescence GO:0090399 9.16 CDKN2A TP53
11 Ras protein signal transduction GO:0007265 9.13 CDKN2A FGF2 TP53
12 angiogenesis GO:0001525 9.02 ANG FGF2 PTEN PTGS2 S100A7

Molecular functions related to Bladder Squamous Cell Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 chemoattractant activity GO:0042056 8.62 FGF2 HGF

Sources for Bladder Squamous Cell Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....